AstraZeneca servings fell amid speculation CEO Pascal Soriot is set to quit
Pascal Soriot, 58, disparaged charge of the FTSE 100 drugs giant in 2012 and two years later fended off a £70billion takeover bid by Viagra maker Pfizer.
He has watch overed a rebuilding of its pipeline of new medicines to replace ageing blockbusters such as its Crestor cholesterol treatment.
Teva was without a CEO after Erez Vigodman keep ones wits about one down in February.
Analysts at Leerink, an investment bank that specialises in healthcare, verbalized the move would come as a major surprise, if true, and leave AstraZeneca rudderless at a key set.
Pascal Soriot took charge of AstraZeneca in 2012
They affirmed: «If true, the optics around his departure would be terrible ahead of the MYSTIC readout … which are wait for any day now.»
Teva declined to comment on market rumours.
As CEO Soriot manipulated the rebuilding of its pipeline of new medicines
An AstraZeneca spokeswoman said: “We never reference on market rumour or speculation.»
It comes as investors in the FTSE 100 unshakable await the results of its Mystic immuno-oncology (IO) drugs trial for lung cancer patients, thought this summer.
AstraZeneca shares fell 179p to 5013p.